Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 1996

View Archived Issues

New analgesic compounds with novel mechanism of action disclosed by Novo Nordisk

Anti-E-selectin antisense compound from Isis inhibits mRNA splicing

ChemGenics/Wyeth-Ayerst antibacterial drug discovery collaboration

Cytovene approved for new indication in U.S.

Connective Therapeutics acquires rheumatoid arthritis Rx from SKB

PAI-1 diagnostic approved for marketing in U.S.

Successful pivotal Mexican trial for oral impotency therapy

Varian, University of Arizona collaborate on methods of enhancing gene therapy efficacy

FDA tentatively approves generic NSAID

SKB, IDEC initiate phase III testing of antirheumatic antibody

Oncogene Science issued patent on gene transcription

Cytel to implement new development strategy for HBV vaccine

Etex signs marketing agreement for bone substitute

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.